LEADING ALUMNI


Unlocking the potential of jellyfish for regenerative medicine

How a Heriot-Watt University alum has created a new class of collagen.

Headshot of Andrew Mearns-Spragg

Dr Andrew Mearns Spragg Founder, Jellagen Ltd


Double alum and marine biotechnology entrepreneur, Dr Andrew Mearns Spragg, is the Founder of Jellagen Ltd, a company spearheading collagen chemistry from jellyfish that has multiple possibilities for revolutionising regenerative medicine worldwide.

“The idea of using jellyfish as a source of new natural products was something that I had in the back of my mind for a number of years,” Andrew explains, his interest having been sparked while surfing off the East coast of Scotland and finding himself surrounded by an abundance of the creatures.

“My academic background is in the field of marine biotechnology, and my career has been focused on applying this to harness the chemical diversity of marine micro-organisms as a source of novel life-enhancing compounds and materials,” he comments.

Andrew’s current work has seen him explore collagen – one of the body's fundamental building blocks. “Every mammal is made up of collagen, a fibrous protein that forms a scaffold providing strength and structural support within the body. It’s an essential component of connective tissue and plays a crucial role in helping tissues repair and renew,” Andrew explains. He began to wonder if jellyfish, one of the Earth’s oldest species, might be a source of collagen that would be fundamentally different to that from mammals, which are currently the medical industry standards but possess inherent clinical shortcomings, including cell mismatching, potential inflammatory triggers, and the risk of zoonotic disease transmission.

My career has been focused on harnessing the chemical diversity of marine micro-organisms as a source of novel life-enhancing compounds and materials.”

Dr A Mearns Spragg


Discovering that primitive life offered revolutionary regenerative properties

“Jellyfish first evolved on Earth some 600 million years ago, and so their collagen is an evolutionary ancient chemical template, which all collagens up the tree of life have been derived from,” Andrew explains. Undertaking to test out its potential, he discovered that it displayed the essential properties of mammalian collagens, but as an evolutionary primitive form, had unique behaviours too.

“We’ve termed jellyfish collagen as ‘Type 0’ because it predates by 0.6Bn years the specialised collagen types found in mammals (referred to as Type I or Type II). It represents a new type of collagen, which can be viewed as a stem of all collagens – a precursor for all the matrices of higher animals. Its biocompatibility makes it an ideal candidate for supporting human cells without causing adverse reactions, so it has the potential to revolutionise various medical fields, including wound healing, tissue regeneration, and implantable devices,” he explains.

A sustainable biomaterial in an era of climate change

The collagen in Jellagen’s products is extracted from Rhizostoma spp., commonly known as the Barrel Jellyfish, which is an ancient species of large jellyfish common to the seas around the UK. They are thriving in our era of new environmental conditions of warming oceans, decreasing marine biodiversity, and species translocation via shipping, all of which support the spread of new blooms globally. “Jellyfish collagen is considered a highly sustainable alternative to traditional mammalian sources by combining lower carbon footprints and circular economy integration,” comments Andrew.

We’ve termed jellyfish collagen ‘Type 0’ because it represents a new type of collagen, with the potential to revolutionise wound management, tissue regeneration and implantable devices.”

Dr A Mearns Spragg


Andrew standing on a platform next to a lectern with a dark backdrop behind him and three other speakers sat to his side

Andrew presenting at the international Symposium on Advanced Wound Care (SAWC).

Micrographs of spheroid cell formation cultured in vitro using a jellyfish collagen 3D matrix.

Pioneering marine biotechnology solutions for improved health

The applications appear endless in the way we can transform tissue engineering and regenerative medicine.”

Dr A Mearns Spragg


Andrew studied a BSc degree in Microbiology and a PhD in Marine Biotechnology at Heriot-Watt supervised by Professors David Adams and Grant Burgess. His PhD research sought to harness the chemical diversity of marine micro-organisms for the discovery and development of new antibiotics effective against multi-drug-resistant bacterial pathogens such as MRSA. This research inspired him to form his first marine biotechnology company supported through being awarded a Royal Society of Edinburgh Enterprise Fellowship in 2000.

Recognised many times for his commercial exploitation of marine biotechnologies, Andrew has successfully secured multi-million-pound investment from private investment sources, as well as securing significant funding from competitive grants from the EU and UK. In 2007, he received the Gannochy Innovation Award from the Royal Society of Edinburgh, Scotland’s highest award for innovation, and his entrepreneurial achievements were recognised with the Ernst & Young Entrepreneur of the Year in Health Care for Scotland in 2008.

Having built the world’s first ISO-certified medical device manufacturing plant for jellyfish collagen from scratch, he is currently Jellagen’s Chief Scientific Officer, overseeing the development of Type 0 collagen to become one of the world’s highest-performing collagens. “Having founded Jellagen, I decided to step down from the CEO role to focus my time, knowledge and energy on the scientific potential of the company,” Andrew explains. “It’s an exciting time for us. We recently announced a new strategic partnership with US company Royal Biologics, a leader in advanced wound care, orthobiologics and regenerative medicine, which will help to bring Collagen Type 0 to the US regenerative medicine market.”

The first application of Jellagen’s collagen type 0 innovation is currently in development for advanced wound management, such as the treatment of diabetic foot ulcers. “But the applications appear endless in the way we can transform tissue engineering and regenerative medicine, in everything from soft tissue repair and bone repair to implantable devices and cell culture,” Andrew adds.

Driving real-world impact

Andrew remains engaged with the University and committed to supporting enterprise and entrepreneurialism. “I am grateful to Heriot-Watt for giving me the opportunity to research my lifetime passion for marine science. As a PhD student in the late 1990s/2000, thinking about enterprise and innovation as a path forward to commercially develop new ideas was not as clear as it is today with many excellent initiatives now available. In my case, a chance meeting with a biotechnology entrepreneur and company founder, who was excited by my research to find new antibiotics, changed my thinking and gave me new confidence that ‘kick-started’ my entrepreneurial career winning the Royal Society of Edinburgh Enterprise Fellowship,” Andrew explains.

As a serial founder with more than 26 years of entrepreneurial experience, Andrew offers a powerful connection between academia, industry and policy. “It would be a privilege to give back to Heriot-Watt,” he reflects. “I am passionate about using my experience in creating and scaling companies to support the next generation of entrepreneurs and to deepen engagement with industry to foster innovation.”

Heriot-Watt University shield icon

Help shape the next generation of innovators. Andrew's journey from Heriot-Watt student to pioneering biotechnology entrepreneur demonstrates the transformative impact of education, research and opportunity. Through our Shaping Futures campaign, we're supporting talented students, world-changing research and the facilities needed to tackle global challenges.

Discover how you can help shape the future

Heriot-Watt Watt Club logo
Return to contents
Top of page